Schering-Plough Targets Annual Rate Of 10 Preclinical Compounds By 2005
Executive Summary
Schering-Plough expects to move 10 compounds from discovery into preclinical development each year by 2005.
You may also be interested in...
Schering Compliance Team Will Report To CEO Following COO Resignation
Schering-Plough's compliance team for resolving FDA's Good Manufacturing Practices concerns with the company will report directly to CEO Richard Kogan following the resignation of President & Chief Operating Officer Raul Cesan.
Pfizer ACAT Inhibitor Phase III Underway; Zocor, Lipitor Prepare For Crestor
Pfizer will receive Phase III data on the anti-atherosclerotic agent avasimibe during 2001, Worldwide Development President Peter Corr told a Pfizer securities analysts meeting Dec. 11 in New York City.
Schering To Market Loratadine Metabolite As Aerius In Europe
Schering-Plough has decided on Aerius as the primary European brand name for desloratadine.